Published in Gene Therapy Weekly, January 27th, 2005
"RNA interference has emerged as a powerful technology for down-regulation of specific genes in cells and animals. We have pioneered macrolide- and tetracycline-adjustable short interfering RNA (siRNA) expression for conditional target gene translation fine-tuning in mammalian/human cell lines based on modified RNA polymerase II promoters," scientists writing in the journal Biotechnology and Bioengineering report.
"Established macrolide- and tetracycline-dependent transactivators/trans-silencers bound and activated modified target promoters tailored for optimal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.